What are the issues facing Parkinson's disease patients at ten years of disease and beyond?: Data from the NPF-QII study

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 3, 2012, Pages

  Hassan, Anhar ^a   Wu, Samuel S ^b   Schmidt, Peter ^c   Malaty, Irene A ^a   Dai, Yun Feng ^b   Miyasaki, Janis M ^d   Okun, Michael S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b National Parkinson's Foundation ^*  (United States)

^c National Parkinson Foundation   (United States)

^d TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Caregiver strain; Complications; Long term; Parkinson's disease; Survival

Indexed keywords

ANTIDEPRESSANT AGENT; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; LEVODOPA; MEMANTINE; NEUROLEPTIC AGENT; RIVASTIGMINE;

ADULT; AGED; ARTHRITIS; ARTICLE; BRAIN DEPTH STIMULATION; CAREGIVER BURDEN; COGNITIVE DEFECT; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL THERAPY; ONSET AGE; PARKINSON DISEASE; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; SPEECH THERAPY; TREATMENT OUTCOME; TREMOR;

AGED; CAREGIVERS; COHORT STUDIES; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TIME FACTORS;

EID: 84870517585     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.06.014     Document Type: Article

References (30)

1. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5(6):525-535.
2. National Parkinson Foundation website.
3. Lim S.Y., Lang A.E. The nonmotor symptoms of Parkinson's disease-an overview. Mov Disord 2010, 25(Suppl. 1):S123-S130.
4. Razali R., Ahmad F., Rahman F.N., Midin M., Sidi H. Burden of care among caregivers of patients with Parkinson disease: a cross-sectional study. Clin Neurol Neurosurg 2011, 113(8):639-643.
5. Dodel R.C., Berger K., Oertel W.H. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001, 19(10):1013-1038.
6. Raggi A., Leonardi M., Covelli V., Albanese A., Soliveri P., Carella F., et al. Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease. Neurol Sci 2011 Nov 10, [Epub ahead of print].
7. Morgante L., Salemi G., Meneghini F., Di Rosa A.E., Epifanio A., Grigoletto F., et al. Parkinson disease survival. Arch Neurol 2000, 57:507-512.
8. D'Amelio M., Ragonese P., Morgante L., Reggio A., Callari G., Salemi G., et al. Long-term survival of Parkinson's disease. A population based study. J Neurol 2006, 253:33-37.
9. Guttman M., Slaughter P.M., Theriault M.E., DeBoer D.P., Naylor C.D. Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 2001, 57(12):2278-2282.
10. Allyson Jones C., Wayne Martin W.R., Wieler M., King-Jesso P., Voaklander D.C. Incidence and mortality of Parkinson's disease in older Canadians. Parkinsonism Relat Disord 2012, 18(4):327-331.
11. Posada I.J., Benito-León J., Louis E.D., Trincado R., Villarejo A., Medrano M.J., et al. Mortality from Parkinson's disease: a population-based prospective study (NEDICES). Mov Disord 2011, 10.1002/mds.23921.
12. Willis A.W., Schootman M., Kung N., Evanoff B.A., Perlmutter J.S., Racette B.A. Predictors of survival in patients with Parkinson disease. Arch Neurol 2012, 10.1001/archneurol.2011.2370.
13. Forsaa E.B., Larsen J.P., Wentzel-Larsen T., Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 2010, 75(14):1270-1276.
14. Hely M.A., Reid W.G.J., Adena M.A., Halliday G.M., Morris J.G.L. Mov Disord 2008, 23(6):837-844.
15. Hely M.A., Morris J.G.L., Reid W.G.J., Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa responsive problems dominate at 15 years. Mov Disord 2005, 20(2):190-199.
16. Ben-Shlomo Y., Marmot M.G. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?. J Neurol Neurosurg Psychiatr 1995, 58:293-299.
17. Diem-Zangerl A., Seppi K., Wenning G.K., Trinka E., Ransmayr G., Oberaigner W., et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009, 24:819-825.
18. Auyeung M., Tsoi T.H., Mok V., Cheung C.M., Lee C.N., Li R., et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. J Neurol Neurosurg Psychiatr 2012, 10.1136/jnnp-2011-301590.
19. Litvan I., Bhatia K.P., Burn D.J., Goetz C.G., Lang A.E., McKeith I., et al. Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003, 18:467-486.
20. Hely M.A., Morris J.G.L., Traficante R., Reid W.G.J., O'Sullivan D.J., Williamson P.M. The Sydney multicenter study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatr 1999, 67:300-307.
21. Bronstein J.M., Tagliati M., Alterman R.L., Lozano A.M., Volkmann J., Stefani A., et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011, 68(2):165-171.
22. Okun M.S., Siderowf A., Nutt J.G., O'Conner G.T., Bloem B.R., Olmstead E.M., et al. Piloting the NP data-driven quality improvement initiative. Parkinsonism Relat Disord 2010, 16(8):517-521.
23. Morris S., Morris M.E., Iansek R. Reliability of measurements obtained with the timed 'up & go' test in people with Parkinson disease. Phys Ther 2001, 81:810-818.
24. Peto V., Jenkinson C., Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998 May, 245(Suppl. 1):S10-S14.
25. Stull D.E. The multidimensional caregiver strain index (MCSI): its measurement and structure. J Clin Geropsychol 1996, 2(3):175e196.
26. Schneider M.G., Swearingen C.J., Shulman L.M., Ye J., Baumgarten M., Tilley B.C. Minority enrollment in Parkinson's disease clinical trials. Parkinsonism Relat Disord 2009 May, 15(4):258-262.
27. Marras C., McDermott M.P., Rochon P.A., Tanner C.M., Naglie G., Rudolph A., et al. Parkinson study group. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005, 64(1):87-93.
28. Willis A.W., Schootman M., Evanoff B.A., Perlmutter J.S., Racette B.A. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology 2011, 77(9):851-857.
29. Goetz C.G., Stebbins G.T. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993, 43:2227-2229.
30. Factor S.A., Feustel P.J., Friedman J.H., Comella C.L., Goetz C.G., Kurlan R., et al. Parkinson study group. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003, 60(11):1756-1761.